4//SEC Filing
Uger Robert 4
Accession 0001062993-21-002721
CIK 0001616212other
Filed
Mar 14, 8:00 PM ET
Accepted
Mar 15, 5:12 PM ET
Size
8.5 KB
Accession
0001062993-21-002721
Insider Transaction Report
Form 4
Uger Robert
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Shares
2021-03-12$3.39/sh+2,917$9,896→ 2,917 total - Sale
Common Shares
2021-03-12$11.97/sh−2,917$34,916→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-12−2,917→ 58,333 totalExercise: $3.39Exp: 2028-11-08→ Common Shares (2,917 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8020 USD.
- [F3]25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.
Issuer
Trillium Therapeutics Inc.
CIK 0001616212
Entity typeother
Related Parties
1- filerCIK 0001838047
Filing Metadata
- Form type
- 4
- Filed
- Mar 14, 8:00 PM ET
- Accepted
- Mar 15, 5:12 PM ET
- Size
- 8.5 KB